Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.

Wennström, Malin LU ; Nielsen, Henrietta LU ; Orhan, Funda ; Londos, Elisabet LU ; Minthon, Lennart LU and Erhardt, Sophie (2014) In International journal of tryptophan research : IJTR 7. p.1-7
Abstract
Kynurenic acid (KYNA) is implicated in cognitive functions. Altered concentrations of the compound are found in serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD). Further studies to determine whether KYNA serves as a biomarker for cognitive decline and dementia progression are required. In this study, we measured CSF KYNA levels in AD patients (n = 19), patients with dementia with Lewy bodies (DLB) (n = 18), and healthy age-matched controls (Ctrls)) (n = 20) to further explore possible correlations between KYNA levels, cognitive decline, and well-established AD and inflammatory markers. Neither DLB patients nor AD patients showed significantly altered CSF KYNA levels compared to Ctrls. However, female AD... (More)
Kynurenic acid (KYNA) is implicated in cognitive functions. Altered concentrations of the compound are found in serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD). Further studies to determine whether KYNA serves as a biomarker for cognitive decline and dementia progression are required. In this study, we measured CSF KYNA levels in AD patients (n = 19), patients with dementia with Lewy bodies (DLB) (n = 18), and healthy age-matched controls (Ctrls)) (n = 20) to further explore possible correlations between KYNA levels, cognitive decline, and well-established AD and inflammatory markers. Neither DLB patients nor AD patients showed significantly altered CSF KYNA levels compared to Ctrls. However, female AD patients displayed significantly higher KYNA levels compared to male AD patients, a gender difference not seen in the Ctrl or DLB group. Levels of KYNA significantly correlated with the AD-biomarker P-tau and the inflammation marker soluble intercellular adhesion molecule-1 (sICAM-1) in the AD patient group. No associations between KYNA and cognitive functions were found. Our study shows that, although KYNA was not associated with cognitive decline in AD or DLB patients, it may be implicated in AD-related hyperphosphorylation of tau and inflammation. Further studies on larger patient cohorts are required to understand the potential role of KYNA in AD and DLB. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International journal of tryptophan research : IJTR
volume
7
pages
1 - 7
publisher
Libertas Academica
external identifiers
  • pmid:24855376
  • scopus:84900032495
  • pmid:24855376
ISSN
1178-6469
DOI
10.4137/IJTR.S13958
language
English
LU publication?
yes
id
0d718bea-fc66-41d1-b1e0-2fde579ff7df (old id 4452628)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24855376?dopt=Abstract
date added to LUP
2016-04-01 14:40:04
date last changed
2022-04-14 19:01:23
@article{0d718bea-fc66-41d1-b1e0-2fde579ff7df,
  abstract     = {{Kynurenic acid (KYNA) is implicated in cognitive functions. Altered concentrations of the compound are found in serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD). Further studies to determine whether KYNA serves as a biomarker for cognitive decline and dementia progression are required. In this study, we measured CSF KYNA levels in AD patients (n = 19), patients with dementia with Lewy bodies (DLB) (n = 18), and healthy age-matched controls (Ctrls)) (n = 20) to further explore possible correlations between KYNA levels, cognitive decline, and well-established AD and inflammatory markers. Neither DLB patients nor AD patients showed significantly altered CSF KYNA levels compared to Ctrls. However, female AD patients displayed significantly higher KYNA levels compared to male AD patients, a gender difference not seen in the Ctrl or DLB group. Levels of KYNA significantly correlated with the AD-biomarker P-tau and the inflammation marker soluble intercellular adhesion molecule-1 (sICAM-1) in the AD patient group. No associations between KYNA and cognitive functions were found. Our study shows that, although KYNA was not associated with cognitive decline in AD or DLB patients, it may be implicated in AD-related hyperphosphorylation of tau and inflammation. Further studies on larger patient cohorts are required to understand the potential role of KYNA in AD and DLB.}},
  author       = {{Wennström, Malin and Nielsen, Henrietta and Orhan, Funda and Londos, Elisabet and Minthon, Lennart and Erhardt, Sophie}},
  issn         = {{1178-6469}},
  language     = {{eng}},
  pages        = {{1--7}},
  publisher    = {{Libertas Academica}},
  series       = {{International journal of tryptophan research : IJTR}},
  title        = {{Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.}},
  url          = {{https://lup.lub.lu.se/search/files/4097857/4930092.pdf}},
  doi          = {{10.4137/IJTR.S13958}},
  volume       = {{7}},
  year         = {{2014}},
}